Published in Ochsner J on January 01, 2017
Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 6.31
Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet (2012) 4.85
Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med (2008) 4.32
Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant (2009) 3.43
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Rejection of the kidney allograft. N Engl J Med (2010) 3.30
Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant (2012) 2.46
Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant (2012) 2.28
Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant (2009) 2.27
Pros and cons for C4d as a biomarker. Kidney Int (2012) 2.03
Summary of FDA antibody-mediated rejection workshop. Am J Transplant (2011) 1.87
Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int (1993) 1.80
Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant (2013) 1.77
Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol (2001) 1.72
Human renal transplants. II. Immunofluorescent and immunoferritin studies. Lab Invest (1968) 1.69
Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol (2004) 1.68
Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant (2009) 1.67
Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant (2011) 1.66
Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation (2014) 1.62
Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation (1998) 1.57
Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant (2009) 1.52
A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation (2009) 1.49
Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation (2007) 1.41
Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant (2007) 1.40
Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant (2013) 1.36
Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant (2012) 1.31
Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant (2014) 1.29
Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant (2009) 1.22
Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol (2012) 1.21
Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transplant (2010) 1.11
Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts. J Am Soc Nephrol (2015) 1.00
Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation (2008) 1.00
Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation (2009) 0.94
A personal perspective: 100-year history of the humoral theory of transplantation. Transplantation (2012) 0.93
Desensitization in kidney transplantation: review and future perspectives. Clin Transplant (2014) 0.90
Quantifying renal allograft loss following early antibody-mediated rejection. Am J Transplant (2015) 0.88
Functional heterogeneity of anti-endothelial cell antibodies. Clin Exp Immunol (2001) 0.88
Diagnostic challenges in chronic antibody-mediated rejection. Nat Rev Nephrol (2012) 0.88
Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience. Ther Apher Dial (2009) 0.87
Multiple hyperacute rejections in the absence of detectable complement activation in a patient with endothelial cell reactive antibody. Am J Transplant (2012) 0.86
The association of antivascular endothelial cell antibody with hyperacute rejection: a case report. Surgery (1986) 0.84
Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options. Pharmacotherapy (2014) 0.82
Impact of maintenance immunosuppressive regimens--balance between graft protective suppression of immune functions and a near physiological immune response. Transpl Int (2011) 0.82
Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation. Am J Transplant (2010) 0.82
Kidney transplantation in highly sensitized patients. Br Med Bull (2015) 0.81
A controlled trial of plasmapheresis in the treatment of renal allograft rejection. Transplantation (1981) 0.81
Transplant immuno-diagnostics: crossmatch and antigen detection. Pediatr Nephrol (2015) 0.80
The importance of non-HLA antibodies in transplantation. Nat Rev Nephrol (2016) 0.80
New insights in antibody-mediated rejection. Curr Opin Nephrol Hypertens (2014) 0.80
Desensitization strategies enabling successful renal transplantation in highly sensitized patients. Clin Transplant (2006) 0.80
Immunoadsorption in nephrology and kidney transplantation. Nephrol Dial Transplant (2010) 0.79
Antibody-mediated rejection after alemtuzumab induction: incidence, risk factors, and predictors of poor outcome. Transplantation (2011) 0.79
Plasma exchange in acute renal transplant rejection. Prog Clin Biol Res (1990) 0.79
Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection. Nephrol Dial Transplant (2014) 0.79
Plasma exchange in acute renal allograft rejection. A controlled trial. Transplantation (1983) 0.79
Non-HLA antibodies against endothelial targets bridging allo- and autoimmunity. Kidney Int (2016) 0.79
Effects of plasmapheresis in renal transplant rejection. A controlled study. Trans Am Soc Artif Intern Organs (1985) 0.78
The clinical impact of chronic transplant glomerulopathy in cyclosporine era. Transplantation (2005) 0.78
Presentation and Outcomes of C4d-Negative Antibody-Mediated Rejection After Kidney Transplantation. Am J Transplant (2015) 0.77
Current outcomes of chronic active antibody mediated rejection - A large single center retrospective review using the updated BANFF 2013 criteria. Hum Immunol (2016) 0.76
Eculizumab for Treatment of Refractory Antibody-Mediated Rejection in Kidney Transplant Patients: A Single-Center Experience. Transplant Proc (2015) 0.76
Development and validation of a prognostic index for allograft outcome in kidney recipients with transplant glomerulopathy. Kidney Int (2016) 0.76
Technical and clinical experience with protein A immunoadsorption columns. Transfus Sci (1994) 0.76
New approaches for desensitization strategies prior to kidney transplantation. Am J Kidney Dis (2009) 0.76
AJKD Atlas of Renal Pathology: Chronic Antibody-Mediated Rejection. Am J Kidney Dis (2015) 0.76
Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management. Curr Transplant Rep (2014) 0.76
Robotic-assisted laparoscopic donor nephrectomy: decreasing length of stay. Ochsner J (2015) 0.90
Novel Biliary Reconstruction Techniques During Liver Transplantation. Ochsner J (2017) 0.75
Balloon-Occlusion Technique for Managing Portal Vein Hemorrhage in Liver Transplantation. Ochsner J (2017) 0.75
Cyclin D1 in the Liver: Role of Noncanonical Signaling in Liver Steatosis and Hormone Regulation. Ochsner J (2017) 0.75
Post-Liver Transplant Delirium Increases Mortality and Length of Stay. Ochsner J (2017) 0.75
Role of Special Coagulation Studies for Preoperative Screening of Thrombotic Complications in Simultaneous Pancreas-Kidney Transplantation. Ochsner J (2015) 0.75